KR20190045354A - 티로신 키나아제 저해제 및 이의 응용 - Google Patents
티로신 키나아제 저해제 및 이의 응용 Download PDFInfo
- Publication number
- KR20190045354A KR20190045354A KR1020197010451A KR20197010451A KR20190045354A KR 20190045354 A KR20190045354 A KR 20190045354A KR 1020197010451 A KR1020197010451 A KR 1020197010451A KR 20197010451 A KR20197010451 A KR 20197010451A KR 20190045354 A KR20190045354 A KR 20190045354A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- compound
- mmol
- washed
- dryness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020217037589A KR102382039B1 (ko) | 2016-09-13 | 2017-06-22 | 티로신 키나아제 저해제 및 이의 응용 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610822529.0 | 2016-09-13 | ||
| CN201610822529.0A CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
| PCT/CN2017/089501 WO2018049861A1 (zh) | 2016-09-13 | 2017-06-22 | 酪氨酸激酶抑制剂及其应用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037589A Division KR102382039B1 (ko) | 2016-09-13 | 2017-06-22 | 티로신 키나아제 저해제 및 이의 응용 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190045354A true KR20190045354A (ko) | 2019-05-02 |
Family
ID=59982910
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197010451A Ceased KR20190045354A (ko) | 2016-09-13 | 2017-06-22 | 티로신 키나아제 저해제 및 이의 응용 |
| KR1020217037589A Active KR102382039B1 (ko) | 2016-09-13 | 2017-06-22 | 티로신 키나아제 저해제 및 이의 응용 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037589A Active KR102382039B1 (ko) | 2016-09-13 | 2017-06-22 | 티로신 키나아제 저해제 및 이의 응용 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10882853B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3511327B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7487921B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20190045354A (cg-RX-API-DMAC10.html) |
| CN (2) | CN110437145A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017325641B2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2902549T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018049861A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3655406A1 (en) | 2017-07-18 | 2020-05-27 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| CN112358469A (zh) * | 2020-03-18 | 2021-02-12 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| AU2009303602B2 (en) * | 2008-10-14 | 2012-06-14 | Sunshine Lake Pharma Co., Ltd. | Compounds and methods of use |
| EP2408300B1 (en) * | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| US8664244B2 (en) | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN105884695B (zh) * | 2015-02-13 | 2019-02-26 | 山东轩竹医药科技有限公司 | 杂环衍生物类酪氨酸激酶抑制剂 |
| CN104817497B (zh) * | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN105017163A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| CN105218445B (zh) * | 2015-08-25 | 2018-05-22 | 江苏中邦制药有限公司 | 一种酪氨酸激酶抑制剂Foretinib的制备方法 |
| CN105085416A (zh) * | 2015-08-25 | 2015-11-25 | 佛山市赛维斯医药科技有限公司 | 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
| CN105001168A (zh) * | 2015-08-25 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 |
-
2016
- 2016-09-13 CN CN201910822704.XA patent/CN110437145A/zh active Pending
- 2016-09-13 CN CN201610822529.0A patent/CN107235896B/zh active Active
-
2017
- 2017-06-22 JP JP2019515307A patent/JP7487921B2/ja active Active
- 2017-06-22 AU AU2017325641A patent/AU2017325641B2/en not_active Ceased
- 2017-06-22 EP EP17850066.6A patent/EP3511327B1/en not_active Not-in-force
- 2017-06-22 KR KR1020197010451A patent/KR20190045354A/ko not_active Ceased
- 2017-06-22 US US16/333,050 patent/US10882853B2/en active Active
- 2017-06-22 WO PCT/CN2017/089501 patent/WO2018049861A1/zh not_active Ceased
- 2017-06-22 ES ES17850066T patent/ES2902549T3/es active Active
- 2017-06-22 KR KR1020217037589A patent/KR102382039B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102382039B1 (ko) | 2022-04-01 |
| US10882853B2 (en) | 2021-01-05 |
| ES2902549T3 (es) | 2022-03-28 |
| EP3511327A4 (en) | 2019-08-07 |
| EP3511327B1 (en) | 2021-10-27 |
| WO2018049861A1 (zh) | 2018-03-22 |
| EP3511327A1 (en) | 2019-07-17 |
| CN107235896B (zh) | 2019-11-05 |
| US20190248772A1 (en) | 2019-08-15 |
| JP7487921B2 (ja) | 2024-05-21 |
| CN110437145A (zh) | 2019-11-12 |
| CN107235896A (zh) | 2017-10-10 |
| AU2017325641A1 (en) | 2019-04-11 |
| AU2017325641B2 (en) | 2021-08-26 |
| KR20210143935A (ko) | 2021-11-29 |
| JP2019529435A (ja) | 2019-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102382039B1 (ko) | 티로신 키나아제 저해제 및 이의 응용 | |
| KR102470598B1 (ko) | 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물 | |
| CN106220635B (zh) | 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮 | |
| KR101971387B1 (ko) | Ask1 억제제의 고체 형태 | |
| EP2312950B1 (en) | Compounds as kinase inhibitors | |
| KR20250073451A (ko) | 신형 prmt5 억제제 및 그 응용 | |
| CN107735399A (zh) | 作为蛋白质激酶的调节剂的手性二芳基大环 | |
| WO2003026665A1 (en) | 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors | |
| JP2023536634A (ja) | 自己免疫疾患および癌の処置のための小分子 | |
| EA029771B1 (ru) | Химические соединения | |
| JP7641965B2 (ja) | 疾患処置に使用するための大環状分子 | |
| CN109776607B (zh) | 芳基磷氧类和芳基磷硫类化合物及其制备方法和应用 | |
| CN111093658A (zh) | 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物 | |
| Chen et al. | O‐Linked Triazolotriazines: Potent and Selective c‐Met Inhibitors | |
| CN120271607A (zh) | Ras抑制剂 | |
| CN102746241B (zh) | 2,3,5-三取代苯甲酰胺类化合物及其制备方法和用途 | |
| CN107235897B (zh) | 酪氨酸激酶抑制剂及其应用 | |
| TW202604504A (zh) | 含氮並環化合物、含其的藥物組合物及其應用 | |
| JP6541635B2 (ja) | Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン | |
| CN122059877A (zh) | 一种萘酰胺类化合物、其制备方法及其应用 | |
| CN118255714A (zh) | 受体酪氨酸激酶抑制剂、其制备方法及其应用 | |
| CN116490507A (zh) | 用于治疗癌症的杂环包缩合cdc7激酶抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20190411 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20200603 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200903 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210520 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20200903 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20210520 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20210104 Comment text: Amendment to Specification, etc. |
|
| PX0601 | Decision of rejection after re-examination |
Comment text: Decision to Refuse Application Patent event code: PX06014S01D Patent event date: 20210818 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20210719 Comment text: Decision to Refuse Application Patent event code: PX06011S01I Patent event date: 20210520 Comment text: Amendment to Specification, etc. Patent event code: PX06012R01I Patent event date: 20210104 Comment text: Notification of reason for refusal Patent event code: PX06013S01I Patent event date: 20200903 |
|
| X601 | Decision of rejection after re-examination | ||
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20211112 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20210818 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Patent event date: 20210520 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20220721 Appeal identifier: 2021101002889 Request date: 20211112 |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20211117 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2021101002889; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20211112 Effective date: 20220721 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20220721 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20211112 Decision date: 20220721 Appeal identifier: 2021101002889 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |